{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T04:11:07Z","timestamp":1793506267658,"version":"4.5.0"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T00:00:00Z","timestamp":1744070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T00:00:00Z","timestamp":1744070400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-025-03821-2","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T12:48:33Z","timestamp":1744116513000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Efficacy and safety of PPAR agonists in primary biliary cholangitis: a systematic review and meta-analysis of Randomized Controlled Trials"],"prefix":"10.1186","volume":"25","author":[{"given":"Behrad","family":"Saeedian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nastaran","family":"Babajani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tannaz","family":"Bagheri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh Ojaghi","family":"Shirmard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Morteza","family":"Pourfaraji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,8]]},"reference":[{"issue":"6","key":"3821_CR1","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.medcli.2017.12.021","volume":"151","author":"A Par\u00e9s","year":"2018","unstructured":"Par\u00e9s A. Primary biliary cholangitis. Med Clin (Barc). 2018;151(6):242\u20139.","journal-title":"Med Clin (Barc)"},{"key":"3821_CR2","doi-asserted-by":"crossref","unstructured":"Trivella J, John BV, Levy C. Primary biliary cholangitis: epidemiology, prognosis, and treatment. Hepatol Commun. 2023;7(6).","DOI":"10.1097\/HC9.0000000000000179"},{"issue":"1","key":"3821_CR3","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","volume":"67","author":"EASL Clinical Practice Guidelines","year":"2017","unstructured":"EASL Clinical Practice Guidelines. The diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017;67(1):145\u201372.","journal-title":"J Hepatol"},{"issue":"3","key":"3821_CR4","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1136\/flgastro-2018-101109","volume":"10","author":"JC Goet","year":"2019","unstructured":"Goet JC, Hirschfield GM. Guideline review: British society of Gastroenterology\/UK-PBC primary biliary cholangitis treatment and management guidelines. Frontline Gastroenterol. 2019;10(3):316\u20139.","journal-title":"Frontline Gastroenterol"},{"issue":"3","key":"3821_CR5","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1053\/j.gastro.2005.12.029","volume":"130","author":"A Par\u00e9s","year":"2006","unstructured":"Par\u00e9s A, Caballer\u00eda L, Rod\u00e9s J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology. 2006;130(3):715\u201320.","journal-title":"Gastroenterology"},{"issue":"2","key":"3821_CR6","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1007\/s00108-016-0185-9","volume":"58","author":"G Gerken","year":"2017","unstructured":"Gerken G, Nitschmann S. [Obeticholic acid in primary biliary cholangitis: PBC OCA international study of efficacy (POISE)]. Internist (Berl). 2017;58(2):202\u20134.","journal-title":"Internist (Berl)"},{"issue":"1","key":"3821_CR7","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13643-024-02460-0","volume":"13","author":"W Lin","year":"2024","unstructured":"Lin W, Wang JX, Liu YJ. Optimal drug regimens for improving ALP biochemical levels in patients with primary biliary cholangitis refractory to UDCA: a systematic review and bayesian network meta-analysis. Syst Rev. 2024;13(1):46.","journal-title":"Syst Rev"},{"key":"3821_CR8","doi-asserted-by":"publisher","first-page":"100188","DOI":"10.1016\/j.jtauto.2023.100188","volume":"6","author":"F Colapietro","year":"2023","unstructured":"Colapietro F, Gershwin ME, Lleo A. PPAR agonists for the treatment of primary biliary cholangitis: old and new Tales. J Transl Autoimmun. 2023;6:100188.","journal-title":"J Transl Autoimmun"},{"issue":"6","key":"3821_CR9","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s00535-002-1102-7","volume":"38","author":"T Kanda","year":"2003","unstructured":"Kanda T, Yokosuka O, Imazeki F, Saisho H. Bezafibrate treatment: a new medical approach for PBC patients? J Gastroenterol. 2003;38(6):573\u20138.","journal-title":"J Gastroenterol"},{"issue":"10","key":"3821_CR10","doi-asserted-by":"publisher","first-page":"3037","DOI":"10.1007\/s10620-016-4250-y","volume":"61","author":"VS Hegade","year":"2016","unstructured":"Hegade VS, Khanna A, Walker LJ, Wong LL, Dyson JK, Jones DEJ. Long-term fenofibrate treatment in primary biliary cholangitis improves biochemistry but not the UK-PBC risk score. Dig Dis Sci. 2016;61(10):3037\u201344.","journal-title":"Dig Dis Sci"},{"key":"3821_CR11","doi-asserted-by":"crossref","unstructured":"Can\u00e7ado GGL, Couto CA, Guedes LV, Braga MH, Terrabuio DRB, Can\u00e7ado ELR, et al. Fibrates for the treatment of primary biliary cholangitis unresponsive to ursodeoxycholic acid: an exploratory study. Front Pharmacol. 2022;12.","DOI":"10.3389\/fphar.2021.818089"},{"issue":"5","key":"3821_CR12","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1002\/hep.26155","volume":"57","author":"NS Ghonem","year":"2013","unstructured":"Ghonem NS, Boyer JL. Fibrates as adjuvant therapy for chronic cholestatic liver disease: its time has come. Hepatology. 2013;57(5):1691\u20133.","journal-title":"Hepatology"},{"issue":"10","key":"3821_CR13","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1111\/hepr.13361","volume":"49","author":"S Joshita","year":"2019","unstructured":"Joshita S, Umemura T, Yamashita Y, Sugiura A, Yamazaki T, Fujimori N, et al. Biochemical and plasma lipid responses to pemafibrate in patients with primary biliary cholangitis. Hepatol Res. 2019;49(10):1236\u201343.","journal-title":"Hepatol Res"},{"key":"3821_CR14","unstructured":"U.S. Food and Drug Administration CfDEaR. Novel Drug Approvals for 2024 2025 [Available from: https:\/\/www.fda.gov\/drugs\/novel-drug-approvals-fda\/novel-drug-approvals-2024"},{"issue":"1","key":"3821_CR15","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jhep.2021.08.025","volume":"76","author":"R Vuppalanchi","year":"2022","unstructured":"Vuppalanchi R, Caldwell SH, Pyrsopoulos N, deLemos AS, Rossi S, Levy C, et al. Proof-of-concept study to evaluate the safety and efficacy of Saroglitazar in patients with primary biliary cholangitis. J Hepatol. 2022;76(1):75\u201385.","journal-title":"J Hepatol"},{"issue":"1","key":"3821_CR16","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","volume":"10","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021;10(1):89.","journal-title":"Syst Rev"},{"key":"3821_CR17","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JPT Higgins","year":"2011","unstructured":"Higgins JPT, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD, et al. The Cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.","journal-title":"BMJ"},{"key":"3821_CR18","unstructured":"Cochrane. Risk of Bias Assessment Tool (RoB2). Available from: https:\/\/methods.cochrane.org\/bias\/resources\/rob-2-revised-cochrane-risk-bias-tool-randomized-trials"},{"issue":"6","key":"3821_CR19","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1177\/0962280216669183","volume":"27","author":"D Luo","year":"2018","unstructured":"Luo D, Wan X, Liu J, Tong T. Optimally estimating the sample mean from the sample size, median, mid-range, and\/or mid-quartile range. Stat Methods Med Res. 2018;27(6):1785\u2013805.","journal-title":"Stat Methods Med Res"},{"key":"3821_CR20","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","volume":"14","author":"X Wan","year":"2014","unstructured":"Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol. 2014;14:135.","journal-title":"BMC Med Res Methodol"},{"key":"3821_CR21","unstructured":"Higgins JPTTJ, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane handbook for systematic reviews of interventions. Version 6.4 (updated August 2023). Cochrane, 2023. Available from: www.training.cochrane.org\/handbook"},{"issue":"7414","key":"3821_CR22","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557\u201360.","journal-title":"BMJ"},{"issue":"7109","key":"3821_CR23","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629\u201334.","journal-title":"BMJ"},{"issue":"7650","key":"3821_CR24","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Sch\u00fcnemann HJ. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924\u20136.","journal-title":"BMJ"},{"issue":"7651","key":"3821_CR25","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1136\/bmj.39490.551019.BE","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Sch\u00fcnemann HJ. What is quality of evidence and why is it important to clinicians? BMJ. 2008;336(7651):995\u20138.","journal-title":"BMJ"},{"issue":"7652","key":"3821_CR26","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1136\/bmj.39493.646875.AE","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Kunz R, Falck-Ytter Y, Vist GE, Liberati A, Sch\u00fcnemann HJ. Going from evidence to recommendations. BMJ. 2008;336(7652):1049\u201351.","journal-title":"BMJ"},{"issue":"1","key":"3821_CR27","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1111\/j.1572-0241.2000.01667.x","volume":"95","author":"S Nakai","year":"2000","unstructured":"Nakai S, Masaki T, Kurokohchi K, Deguchi A, Nishioka M. Combination therapy of bezafibrate and ursodeoxycholic acid in primary biliary cirrhosis: a preliminary study. Am J Gastroenterol. 2000;95(1):326\u20137.","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"3821_CR28","doi-asserted-by":"publisher","first-page":"2990","DOI":"10.1111\/j.1572-0241.2000.03220.x","volume":"95","author":"T Kurihara","year":"2000","unstructured":"Kurihara T, Niimi A, Maeda A, Shigemoto M, Yamashita K. Bezafibrate in the treatment of primary biliary cirrhosis: comparison with ursodeoxycholic acid. Am J Gastroenterol. 2000;95(10):2990\u20132.","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"3821_CR29","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.hepres.2004.04.001","volume":"29","author":"J Itakura","year":"2004","unstructured":"Itakura J, Izumi N, Nishimura Y, Inoue K, Ueda K, Nakanishi H, et al. Prospective randomized crossover trial of combination therapy with bezafibrate and UDCA for primary biliary cirrhosis. Hepatol Res. 2004;29(4):216\u201322.","journal-title":"Hepatol Res"},{"issue":"6","key":"3821_CR30","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1111\/j.1872-034X.2007.00305.x","volume":"38","author":"S Iwasaki","year":"2008","unstructured":"Iwasaki S, Ohira H, Nishiguchi S, Zeniya M, Kaneko S, Onji M, et al. The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: A prospective, multicenter study. Hepatol Res. 2008;38(6):557\u201364.","journal-title":"Hepatol Res"},{"issue":"3","key":"3821_CR31","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/ajg.2015.20","volume":"110","author":"K Hosonuma","year":"2015","unstructured":"Hosonuma K, Sato K, Yamazaki Y, Yanagisawa M, Hashizume H, Horiguchi N, et al. A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and Bezafibrate in patients with primary biliary cirrhosis and dyslipidemia. Am J Gastroenterol. 2015;110(3):423\u201331.","journal-title":"Am J Gastroenterol"},{"issue":"23","key":"3821_CR32","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1056\/NEJMoa1714519","volume":"378","author":"C Corpechot","year":"2018","unstructured":"Corpechot C, Chazouill\u00e8res O, Rousseau A, Le Gruyer A, Habersetzer F, Mathurin P, et al. A placebo-controlled trial of bezafibrate in primary biliary cholangitis. N Engl J Med. 2018;378(23):2171\u201381.","journal-title":"N Engl J Med"},{"issue":"3","key":"3821_CR33","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1053\/j.gastro.2020.10.001","volume":"160","author":"E de Vries","year":"2021","unstructured":"de Vries E, Bolier R, Goet J, Par\u00e9s A, Verbeek J, de Vree M, et al. Fibrates for itch (FITCH) in fibrosing cholangiopathies: a double-blind, randomized, placebo-controlled trial. Gastroenterology. 2021;160(3):734\u2013e436.","journal-title":"Gastroenterology"},{"key":"3821_CR34","doi-asserted-by":"publisher","first-page":"120","DOI":"10.2174\/1874192401004010120","volume":"4","author":"EN Liberopoulos","year":"2010","unstructured":"Liberopoulos EN, Florentin M, Elisaf MS, Mikhailidis DP, Tsianos E. Fenofibrate in primary biliary cirrhosis: a pilot study. Open Cardiovasc Med J. 2010;4:120\u20136.","journal-title":"Open Cardiovasc Med J"},{"key":"3821_CR35","doi-asserted-by":"publisher","first-page":"204062232211141","DOI":"10.1177\/20406223221114198","volume":"13","author":"C Li","year":"2022","unstructured":"Li C, Zheng K, Chen Y, He C, Liu S, Yang Y, et al. A randomized, controlled trial on Fenofibrate in primary biliary cholangitis patients with incomplete response to ursodeoxycholic acid. Ther Adv Chronic Dis. 2022;13:20406223221114198.","journal-title":"Ther Adv Chronic Dis"},{"issue":"11","key":"3821_CR36","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.14309\/ajg.0000000000002238","volume":"118","author":"Y Liu","year":"2023","unstructured":"Liu Y, Guo G, Zheng L, Sun R, Wang X, Deng J, et al. Effectiveness of fenofibrate in treatment-naive patients with primary biliary cholangitis: a randomized clinical trial. Am J Gastroenterol. 2023;118(11):1973\u20139.","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"3821_CR37","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/j.jhep.2021.01.013","volume":"74","author":"JM Schattenberg","year":"2021","unstructured":"Schattenberg JM, Pares A, Kowdley KV, Heneghan MA, Caldwell S, Pratt D, et al. A randomized placebo-controlled trial of Elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA. J Hepatol. 2021;74(6):1344\u201354.","journal-title":"J Hepatol"},{"issue":"9","key":"3821_CR38","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa2306185","volume":"390","author":"KV Kowdley","year":"2024","unstructured":"Kowdley KV, Bowlus CL, Levy C, Akarca US, Alvares-da-Silva MR, Andreone P, et al. Efficacy and safety of elafibranor in primary biliary cholangitis. N Engl J Med. 2024;390(9):795\u2013805.","journal-title":"N Engl J Med"},{"issue":"10","key":"3821_CR39","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/S2468-1253(17)30246-7","volume":"2","author":"D Jones","year":"2017","unstructured":"Jones D, Boudes PF, Swain MG, Bowlus CL, Galambos MR, Bacon BR, et al. Seladelpar (MBX-8025), a selective PPAR-\u03b4 agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study. Lancet Gastroenterol Hepatol. 2017;2(10):716\u201326.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"3821_CR40","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1097\/HEP.0000000000000395","volume":"78","author":"GM Hirschfield","year":"2023","unstructured":"Hirschfield GM, Shiffman ML, Gulamhusein A, Kowdley KV, Vierling JM, Levy C, et al. Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study. Hepatology. 2023;78(2):397\u2013415.","journal-title":"Hepatology"},{"issue":"9","key":"3821_CR41","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJMoa2312100","volume":"390","author":"GM Hirschfield","year":"2024","unstructured":"Hirschfield GM, Bowlus CL, Mayo MJ, Kremer AE, Vierling JM, Kowdley KV, et al. A phase 3 trial of Seladelpar in primary biliary cholangitis. N Engl J Med. 2024;390(9):783\u201394.","journal-title":"N Engl J Med"},{"issue":"5","key":"3821_CR42","doi-asserted-by":"publisher","first-page":"497","DOI":"10.2340\/00015555-1265","volume":"92","author":"A Reich","year":"2012","unstructured":"Reich A, Heisig M, Phan NQ, Taneda K, Takamori K, Takeuchi S, et al. Visual analogue scale: evaluation of the instrument for the assessment of pruritus. Acta Derm Venereol. 2012;92(5):497\u2013501.","journal-title":"Acta Derm Venereol"},{"issue":"11","key":"3821_CR43","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1136\/gut.2005.065862","volume":"54","author":"A Jacoby","year":"2005","unstructured":"Jacoby A, Rannard A, Buck D, Bhala N, Newton JL, James OF, Jones DE. Development, validation, and evaluation of the PBC-40, a disease specific health related quality of life measure for primary biliary cirrhosis. Gut. 2005;54(11):1622\u20139.","journal-title":"Gut"},{"issue":"3","key":"3821_CR44","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1111\/j.1365-2133.2009.09586.x","volume":"162","author":"S Elman","year":"2010","unstructured":"Elman S, Hynan LS, Gabriel V, Mayo MJ. The 5-D itch scale: a new measure of pruritus. Br J Dermatol. 2010;162(3):587\u201393.","journal-title":"Br J Dermatol"},{"issue":"10","key":"3821_CR45","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1016\/j.dld.2022.12.010","volume":"55","author":"J Gazda","year":"2023","unstructured":"Gazda J, Drazilova S, Gazda M, Janicko M, Koky T, Macej M, et al. Treatment response to ursodeoxycholic acid in primary biliary cholangitis: A systematic review and meta-analysis. Dig Liver Dis. 2023;55(10):1318\u201327.","journal-title":"Dig Liver Dis"},{"issue":"1","key":"3821_CR46","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1002\/hep.30145","volume":"69","author":"KD Lindor","year":"2019","unstructured":"Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M, Primary Biliary C. 2018 Practice guidance from the American association for the study of liver diseases. Hepatology. 2019;69(1):394\u2013419.","journal-title":"Hepatology"},{"issue":"18","key":"3821_CR47","doi-asserted-by":"publisher","first-page":"4559","DOI":"10.1021\/jm049904b","volume":"47","author":"R Pellicciari","year":"2004","unstructured":"Pellicciari R, Costantino G, Camaioni E, Sadeghpour BM, Entrena A, Willson TM, et al. Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of Chenodeoxycholic acid. J Med Chem. 2004;47(18):4559\u201369.","journal-title":"J Med Chem"},{"issue":"5","key":"3821_CR48","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1002\/hep.22519","volume":"48","author":"YD Wang","year":"2008","unstructured":"Wang YD, Chen WD, Wang M, Yu D, Forman BM, Huang W. Farnesoid X receptor antagonizes nuclear factor kappab in hepatic inflammatory response. Hepatology. 2008;48(5):1632\u201343.","journal-title":"Hepatology"},{"issue":"7","key":"3821_CR49","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1056\/NEJMoa1509840","volume":"375","author":"F Nevens","year":"2016","unstructured":"Nevens F, Andreone P, Mazzella G, Strasser SI, Bowlus C, Invernizzi P, et al. A Placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med. 2016;375(7):631\u201343.","journal-title":"N Engl J Med"},{"issue":"6","key":"3821_CR50","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/S2468-1253(19)30094-9","volume":"4","author":"M Trauner","year":"2019","unstructured":"Trauner M, Nevens F, Shiffman ML, Drenth JPH, Bowlus CL, Vargas V, et al. Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study. Lancet Gastroenterol Hepatol. 2019;4(6):445\u201353.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"3821_CR51","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1172\/JCI88894","volume":"127","author":"V Dubois","year":"2017","unstructured":"Dubois V, Eeckhoute J, Lefebvre P, Staels B. Distinct but complementary contributions of PPAR isotypes to energy homeostasis. J Clin Invest. 2017;127(4):1202\u201314.","journal-title":"J Clin Invest"},{"issue":"4a","key":"3821_CR52","doi-asserted-by":"publisher","first-page":"j3","DOI":"10.1016\/S0002-9149(03)00610-6","volume":"92","author":"WA Hsueh","year":"2003","unstructured":"Hsueh WA, Law R. The central role of fat and effect of peroxisome proliferator-activated receptor-gamma on progression of insulin resistance and cardiovascular disease. Am J Cardiol. 2003;92(4a):j3\u20139.","journal-title":"Am J Cardiol"},{"issue":"3","key":"3821_CR53","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1002\/hep.24148","volume":"53","author":"M Wagner","year":"2011","unstructured":"Wagner M, Zollner G, Trauner M. Nuclear receptors in liver disease. Hepatology. 2011;53(3):1023\u201334.","journal-title":"Hepatology"},{"issue":"5","key":"3821_CR54","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1002\/hep.26018","volume":"57","author":"A Honda","year":"2013","unstructured":"Honda A, Ikegami T, Nakamuta M, Miyazaki T, Iwamoto J, Hirayama T, et al. Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid. Hepatology. 2013;57(5):1931\u201341.","journal-title":"Hepatology"},{"issue":"2","key":"3821_CR55","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1002\/hep.27744","volume":"62","author":"NS Ghonem","year":"2015","unstructured":"Ghonem NS, Assis DN, Boyer JL. Fibrates and cholestasis. Hepatology. 2015;62(2):635\u201343.","journal-title":"Hepatology"},{"issue":"11","key":"3821_CR56","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1161\/hq1101.098228","volume":"21","author":"SM Post","year":"2001","unstructured":"Post SM, Duez H, Gervois PP, Staels B, Kuipers F, Princen HM. Fibrates suppress bile acid synthesis via peroxisome proliferator-activated receptor-alpha-mediated downregulation of cholesterol 7alpha-hydroxylase and sterol 27-hydroxylase expression. Arterioscler Thromb Vasc Biol. 2001;21(11):1840\u20135.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"11","key":"3821_CR57","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.14309\/ajg.0000000000001343","volume":"116","author":"A Reig","year":"2021","unstructured":"Reig A, \u00c1lvarez-Navascu\u00e9s C, Vergara M, G\u00f3mez-Dom\u00ednguez E, Gallego-Moya A, P\u00e9rez-Medrano IM, et al. Obeticholic acid and fibrates in primary biliary cholangitis: comparative effects in a multicentric observational study. Am J Gastroenterol. 2021;116(11):2250\u20137.","journal-title":"Official J Am Coll Gastroenterol| ACG"},{"issue":"3","key":"3821_CR58","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.jhep.2014.10.039","volume":"62","author":"M Pawlak","year":"2015","unstructured":"Pawlak M, Lefebvre P, Staels B. Molecular mechanism of PPAR\u03b1 action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. J Hepatol. 2015;62(3):720\u201333.","journal-title":"J Hepatol"},{"issue":"6","key":"3821_CR59","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1002\/hep.20705","volume":"41","author":"K Harada","year":"2005","unstructured":"Harada K, Isse K, Kamihira T, Shimoda S, Nakanuma Y. Th1 cytokine-induced downregulation of PPARgamma in human biliary cells relates to cholangitis in primary biliary cirrhosis. Hepatology. 2005;41(6):1329\u201338.","journal-title":"Hepatology"},{"key":"3821_CR60","doi-asserted-by":"crossref","unstructured":"Wang Y, Nakajima T, Gonzalez FJ, Tanaka N. PPARs as metabolic regulators in the liver: lessons from liver-specific PPAR-Null mice. Int J Mol Sci. 2020;21(6).","DOI":"10.3390\/ijms21062061"},{"issue":"3","key":"3821_CR61","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1002\/hep.22428","volume":"48","author":"C Corpechot","year":"2008","unstructured":"Corpechot C, Abenavoli L, Rabahi N, Chr\u00e9tien Y, Andr\u00e9ani T, Johanet C, et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology. 2008;48(3):871\u20137.","journal-title":"Hepatology"},{"issue":"6","key":"3821_CR62","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1016\/j.jhep.2011.02.031","volume":"55","author":"C Corpechot","year":"2011","unstructured":"Corpechot C, Chazouill\u00e8res O, Poupon R. Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome. J Hepatol. 2011;55(6):1361\u20137.","journal-title":"J Hepatol"},{"issue":"10","key":"3821_CR63","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1038\/ajg.2010.216","volume":"105","author":"T Kumagi","year":"2010","unstructured":"Kumagi T, Guindi M, Fischer SE, Arenovich T, Abdalian R, Coltescu C, et al. Baseline ductopenia and treatment response predict Long-Term histological progression in primary biliary cirrhosis. Official J Am Coll Gastroenterol| ACG. 2010;105(10):2186\u201394.","journal-title":"Official J Am Coll Gastroenterol| ACG"},{"issue":"7","key":"3821_CR64","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1053\/j.gastro.2015.07.061","volume":"149","author":"WJ Lammers","year":"2015","unstructured":"Lammers WJ, Hirschfield GM, Corpechot C, Nevens F, Lindor KD, Janssen HL, et al. Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy. Gastroenterology. 2015;149(7):1804\u2013e124.","journal-title":"Gastroenterology"},{"issue":"3","key":"3821_CR65","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1002\/hep.28017","volume":"63","author":"M Carbone","year":"2016","unstructured":"Carbone M, Sharp SJ, Flack S, Paximadas D, Spiess K, Adgey C, et al. The UK-PBC risk scores: derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis. Hepatology. 2016;63(3):930\u201350.","journal-title":"Hepatology"},{"key":"3821_CR66","doi-asserted-by":"publisher","first-page":"948362","DOI":"10.3389\/fphar.2022.948362","volume":"13","author":"X Guoyun","year":"2022","unstructured":"Guoyun X, Dawei D, Ning L, Yinan H, Fangfang Y, Siyuan T, et al. Efficacy and safety of fenofibrate add-on therapy in patients with primary biliary cholangitis refractory to ursodeoxycholic acid: A retrospective study and updated meta-analysis. Front Pharmacol. 2022;13:948362.","journal-title":"Front Pharmacol"},{"issue":"5","key":"3821_CR67","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1007\/s10238-022-00904-2","volume":"23","author":"H Zhang","year":"2023","unstructured":"Zhang H, Li S, Feng Y, Zhang Q, Xie B. Efficacy of fibrates in the treatment of primary biliary cholangitis: a meta-analysis. Clin Exp Med. 2023;23(5):1741\u20139.","journal-title":"Clin Exp Med"},{"key":"3821_CR68","first-page":"Cd009145","volume":"1","author":"JS Rudic","year":"2012","unstructured":"Rudic JS, Poropat G, Krstic MN, Bjelakovic G, Gluud C. Bezafibrate for primary biliary cirrhosis. Cochrane Database Syst Rev. 2012;1:Cd009145.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"3821_CR69","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s10620-024-08742-w","volume":"70","author":"NA Cumpian","year":"2025","unstructured":"Cumpian NA, Choi G, Saab S. Review of current and upcoming second-line treatments for primary biliary cholangitis. Dig Dis Sci. 2025;70(1):100\u201310.","journal-title":"Dig Dis Sci"},{"key":"3821_CR70","first-page":"2757","volume":"9","author":"Y Zhang","year":"2015","unstructured":"Zhang Y, Li S, He L, Wang F, Chen K, Li J, et al. Combination therapy of fenofibrate and ursodeoxycholic acid in patients with primary biliary cirrhosis who respond incompletely to UDCA monotherapy: a meta-analysis. Drug Des Devel Ther. 2015;9:2757\u201366.","journal-title":"Drug Des Devel Ther"},{"key":"3821_CR71","first-page":"5407","volume":"9","author":"Q Yin","year":"2015","unstructured":"Yin Q, Li J, Xia Y, Zhang R, Wang J, Lu W, et al. Systematic review and meta-analysis: bezafibrate in patients with primary biliary cirrhosis. Drug Des Devel Ther. 2015;9:5407\u201319.","journal-title":"Drug Des Devel Ther"},{"issue":"3","key":"3821_CR72","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.clinre.2015.02.011","volume":"39","author":"AY Grigorian","year":"2015","unstructured":"Grigorian AY, Mardini HE, Corpechot C, Poupon R, Levy C. Fenofibrate is effective adjunctive therapy in the treatment of primary biliary cirrhosis: A meta-analysis. Clin Res Hepatol Gastroenterol. 2015;39(3):296\u2013306.","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"1","key":"3821_CR73","first-page":"Cd009145","volume":"1","author":"JS Rudic","year":"2012","unstructured":"Rudic JS, Poropat G, Krstic MN, Bjelakovic G, Gluud C. Bezafibrate for primary biliary cirrhosis. Cochrane Database Syst Rev. 2012;1(1):Cd009145.","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"3821_CR74","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1053\/j.gastro.2014.08.029","volume":"147","author":"WJ Lammers","year":"2014","unstructured":"Lammers WJ, van Buuren HR, Hirschfield GM, Janssen HL, Invernizzi P, Mason AL, et al. Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. Gastroenterology. 2014;147(6):1338\u201349. e5; quiz e15.","journal-title":"Gastroenterology"},{"issue":"4","key":"3821_CR75","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1053\/j.gastro.2009.01.003","volume":"136","author":"EM Kuiper","year":"2009","unstructured":"Kuiper EM, Hansen BE, de Vries RA, den Ouden-Muller JW, van Ditzhuijsen TJ, Haagsma EB, et al. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology. 2009;136(4):1281\u20137.","journal-title":"Gastroenterology"},{"issue":"13","key":"3821_CR76","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1002\/sim.1461","volume":"22","author":"N Terrin","year":"2003","unstructured":"Terrin N, Schmid CH, Lau J, Olkin I. Adjusting for publication bias in the presence of heterogeneity. Stat Med. 2003;22(13):2113\u201326.","journal-title":"Stat Med"},{"issue":"25","key":"3821_CR77","doi-asserted-by":"publisher","first-page":"4544","DOI":"10.1002\/sim.2889","volume":"26","author":"JL Peters","year":"2007","unstructured":"Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Performance of the trim and fill method in the presence of publication bias and between-study heterogeneity. Stat Med. 2007;26(25):4544\u201362.","journal-title":"Stat Med"},{"issue":"43","key":"3821_CR78","first-page":"A6443","volume":"157","author":"SM Goorden","year":"2013","unstructured":"Goorden SM, Buffart TE, Bakker A, Buijs MM. [Liver disorders in adults: ALT and AST]. Ned Tijdschr Geneeskd. 2013;157(43):A6443.","journal-title":"Ned Tijdschr Geneeskd"},{"issue":"7","key":"3821_CR79","doi-asserted-by":"publisher","first-page":"7697","DOI":"10.21037\/apm-21-1304","volume":"10","author":"N Shen","year":"2021","unstructured":"Shen N, Pan J, Miao H, Zhang H, Xing L, Yu X. Fibrates for the treatment of pruritus in primary biliary cholangitis: a systematic review and meta-analysis. Ann Palliat Med. 2021;10(7):7697\u2013705.","journal-title":"Ann Palliat Med"},{"issue":"6","key":"3821_CR80","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1111\/liv.14871","volume":"41","author":"AF Carrion","year":"2021","unstructured":"Carrion AF, Lindor KD, Levy C. Safety of fibrates in cholestatic liver diseases. Liver Int. 2021;41(6):1335\u201343.","journal-title":"Liver Int"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-03821-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-025-03821-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-03821-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T17:10:25Z","timestamp":1744218625000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-025-03821-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,8]]},"references-count":80,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3821"],"URL":"https:\/\/doi.org\/10.1186\/s12876-025-03821-2","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,8]]},"assertion":[{"value":"5 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"230"}}